Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer
Abstract Objective Although targeted approaches have become available in second‐ and third‐line settings, platinum‐based chemotherapy remains the standard first‐line treatment for advanced muscle‐invasive bladder cancer (MIBC). Therefore, the prediction of platinum resistance is of utmost clinical i...
Main Authors: | Csilla Olah, Henning Reis, Michèle J. Hoffmann, Fabian Mairinger, Saskia Ting, Boris Hadaschik, Ulrich Krafft, Viktor Grünwald, Peter Nyirady, Melinda Varadi, Balázs Győrffy, Andras Kiss, Eszter Szekely, Gottfrid Sjödahl, Tibor Szarvas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5324 |
Similar Items
-
Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types
by: Zhishan Chen, et al.
Published: (2019-09-01) -
APOBEC Mutagenesis in Cancer Development and Susceptibility
by: Alexandra Dananberg, et al.
Published: (2024-01-01) -
AID and APOBECs span the gap between innate and adaptive immunity
by: Arnaud eMoris, et al.
Published: (2014-10-01) -
Small-Angle X-ray Scattering Models of APOBEC3B Catalytic Domain in a Complex with a Single-Stranded DNA Inhibitor
by: Fareeda M. Barzak, et al.
Published: (2021-02-01) -
APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome
by: Ebrahimi Diako, et al.
Published: (2012-12-01)